

Package ‘dfcomb’

July 22, 2025

Type Package

Title Phase I/II Adaptive Dose-Finding Design for Combination Studies

Version 3.1-4

Date 2024-09-30

Copyright src/arms.c and src/arms.h are copyright Wally Gilks. All other files are copyright Sanofi-Aventis R&D, Institut de Recherches Internationales Servier and Institut national de la sante et de la recherche medicale.

Description Phase I/II adaptive dose-finding design for combination studies where toxicity rates are supposed to increase with both agents.

License GPL-3

Depends R (>= 3.2.3)

LinkingTo BH (>= 1.55), Rcpp, RcppProgress (>= 0.2.1)

NeedsCompilation yes

Author Marie-Karelle Riviere [aut],
Jacques-Henri Jourdan [aut, cre]

Maintainer Jacques-Henri Jourdan <jacques-henri.jourdan@cnrs.fr>

Repository CRAN

Date/Publication 2024-09-30 15:50:04 UTC

Contents

dfcomb-package	2
CombIncrease_next	3
CombIncrease_sim	6

Index	11
--------------	-----------

dfcomb-package	<i>Phase I/II Adaptive Dose-Finding Design for Combination Studies</i>
----------------	--

Description

Phase I/II adaptive dose-finding design for combination studies where toxicity rates are supposed to increase with both agents.

Details

The DESCRIPTION file:

Package: dfcomb
Type: Package
Title: Phase I/II Adaptive Dose-Finding Design for Combination Studies
Version: 3.1-4
Date: 2024-09-30
Authors@R: c(person(given = "Marie-Karelle", family = "Riviere", role = "aut"), person(given = "Jacques-Henri", fa
Copyright: src/arms.c and src/arms.h are copyright Wally Gilks. All other files are copyright Sanofi-Aventis R&D, I
Description: Phase I/II adaptive dose-finding design for combination studies where toxicity rates are supposed to incr
License: GPL-3
Depends: R (>= 3.2.3)
LinkingTo: BH (>= 1.55), Rcpp, RcppProgress (>= 0.2.1)
NeedsCompilation: yes
Author: Marie-Karelle Riviere [aut], Jacques-Henri Jourdan [aut, cre]
Maintainer: Jacques-Henri Jourdan <jacques-henri.jourdan@cnr.fr>

Index of help topics:

CombIncrease_next	Combination determination with logistic model
CombIncrease_sim	Combination design Simulator using Logistic model
dfcomb-package	Phase I/II Adaptive Dose-Finding Design for Combination Studies

Author(s)

Marie-Karelle Riviere [aut], Jacques-Henri Jourdan [aut, cre]
Maintainer: Jacques-Henri Jourdan <jacques-henri.jourdan@cnr.fr>

References

Riviere MK, Yuan Y, Dubois F, Zohar S (2014). A Bayesian dose-finding design for drug combina-
tion clinical trials based on the logistic model. Pharm Stat, 13, 4:247-57.

CombIncrease_next	<i>Combination determination with logistic model</i>
-------------------	--

Description

CombIncrease_next is used to determine the next or recommended combination in a phase I combination clinical trial using the design proposed by Riviere et al. entitled "A Bayesian dose-finding design for drug combination clinical trials based on the logistic model".

Usage

```
CombIncrease_next(ndose_a1, ndose_a2, target, target_min, target_max,
  prior_tox_a1, prior_tox_a2, cohort, final, pat_incl, dose_adm1,
  dose_adm2, tite=FALSE, toxicity, time_full=0, time_tox=0,
  time_follow=0, c_e=0.85, c_d=0.45, c_stop=0.95, c_t=0.5, c_over=0.25,
  cmin_overunder=2, cmin_mtd=3, cmin_recom=1, early_stop=1, alloc_rule=1,
  nburn=2000, niter=5000)
```

Arguments

ndose_a1	Number of dose levels for agent 1.
ndose_a2	Number of dose levels for agent 2.
target	Toxicity (probability) target.
target_min	Minimum of the targeted toxicity interval.
target_max	Maximum of the targeted toxicity interval.
prior_tox_a1	A vector of initial guesses of toxicity probabilities associated with the doses of agent 1. Must be of length ndose_a1.
prior_tox_a2	A vector of initial guesses of toxicity probabilities associated with the doses of agent 2. Must be of length ndose_a2.
cohort	Cohort size.
final	A boolean with value TRUE if the trial is finished and the recommended combination for further phases should be given, or FALSE (default value) if the combination determination is performed for the next cohort of patients.
pat_incl	Current number of patients included.
dose_adm1	A vector indicating the dose levels of agents 1 administered to each patient included in the trial. Must be of length pat_incl.
dose_adm2	A vector indicating the dose levels of agents 2 administered to each patient included in the trial. Must be of length pat_incl.
tite	A boolean indicating if the toxicity is considered as a time-to-event outcome (TRUE), or as a binary outcome (default value FALSE).
toxicity	A vector of observed toxicities (DLTs) for each patient included in the trial. Must be of length pat_incl. This argument is used/required only if tite=FALSE.
time_full	Full follow-up time window. This argument is used only if tite=TRUE.

time_tox	A vector of times-to-toxicity for each patient included in the trial. If no toxicity was observed for a patient, must be filled with +Inf. Must be of length pat_incl. This argument is used/required only if tite=TRUE.
time_follow	A vector of follow-up times for each patient included in the trial. Must be of length pat_incl. This argument is used/required only if tite=TRUE.
c_e	Probability threshold for dose-escalation. The default value is set at 0.85.
c_d	Probability threshold for dose-deescalation. The default value is set at 0.45.
c_stop	Probability threshold for early trial termination. The default value is set at 0.95.
c_t	Probability threshold for early trial termination for finding the MTD (see details). The default value is set at 0.5.
c_over	Probability threshold to control over-dosing (see details).
cmin_overunder	Minimum number of cohorts to be included at the lowest/highest combination before possible early trial termination for over-toxicity or under-toxicity (see details). The default value is set at 2.
cmin_mtd	Minimum number of cohorts to be included at the recommended combination before possible early trial termination for finding the MTD (see details). The default value is set at 3.
cmin_recom	Minimum number of cohorts to be included at the recommended combination at the end of the trial. The default value is set at 1.
alloc_rule	Integer (1, 2, or 3) indicating which allocation rule is used (see details). The default value is set at 1.
early_stop	Integer (1, 2, or 3) indicating which early stopping rule is used (see details). The default value is set at 1.
nburn	Number of burn-in for HMC. The default value is set at 2000.
niter	Number of iterations for HMC. The default value is set at 5000.

Details

Allocation rule:

- alloc_rule=1 (Riviere et al 2014): If $P(\text{toxicity probability at combination } (i,j) < \text{target}) > c_e$: among combinations in the neighborhood $(-1, +1), (0, +1), (+1, 0), (+1, -1)$, choose the combination with a higher estimated toxicity probability than the current combination and with the estimated toxicity probability closest to target. If $P(\text{toxicity probability at combination } (i,j) > \text{target}) > 1 - c_d$: among neighborhood $(-1, +1), (-1, 0), (0, -1), (+1, -1)$, choose the combination with a lower estimated toxicity probability than the current combination and with the estimated toxicity probability closest to target. Otherwise, remain on the same combination.
- alloc_rule=2: Among combinations already tested and combinations in the neighborhood $(-1, 0), (-1, +1), (0, +1), (+1, 0), (+1, -1), (0, -1), (-1, -1)$ of a combination tested, choose the combination with the highest posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$ while controlling overdosing i.e. $P(\text{toxicity probability at combination } (i,j) > \text{target_max}) < c_{\text{over}}$.

- `alloc_rule=3`: Among combinations in the neighborhood $(-1, 0)$, $(-1, +1)$, $(0, +1)$, $(+1, 0)$, $(+1, -1)$, $(0, -1)$, $(-1, -1)$ of the current combination, choose the combination with the highest posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$ while controlling overdosing i.e. $P(\text{toxicity probability at combination } (i,j) > \text{target_max}) < c_over$.

Early stopping for over-dosing: If the current combination is the lowest $(1, 1)$ and at least `cmin_overunder` cohorts have been included at that combination and $P(\text{toxicity probability at combination } (i,j) > \text{target}) \geq c_stop$ then stop the trial and do not recommend any combination.

Early stopping for under-dosing: If the current combination is the highest and at least `cmin_overunder` cohorts have been included at that combination and $P(\text{toxicity probability at combination } (i,j) < \text{target}) \geq c_stop$ then stop the trial and do not recommend any combination.

Early stopping for identifying the MTD:

- `early_stop=1` (Riviere et al 2014): No stopping rule, include patients until maximum sample size is reached.
- `early_stop=2`: If the next recommended combination has been tested on at least `cmin_mtd` cohorts and has a posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$ that is $\geq c_t$ and also control overdosing i.e. $P(\text{toxicity probability at current combination} > \text{target_max}) < c_over$ then stop the trial and recommend this combination.
- `early_stop=3`: If at least `cmin_mtd` cohorts have been included at the next recommended combination then stop the trial and recommend this combination.

Stopping at the maximum sample size: If the maximum sample size is reached and no stopping rule is met, then the recommended combination is the one that was tested on at least `cmin_recom` cohorts and with the highest posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$.

Value

An object of class "CombIncrease_next" is returned, consisting of determination of the next combination and estimations. Objects generated by `CombIncrease_next` contain at least the following components:

<code>n_pat_comb</code>	Number of patients per combination.
<code>n_tox_comb</code>	Number of observed toxicities per combination.
<code>pi</code>	Estimated toxicity probabilities (if the start-up ended).
<code>ptox_inf</code>	Estimated probabilities that the toxicity probability is inferior to target (if the start-up ended).
<code>ptox_inf_targ</code>	Estimated probabilities of underdosing, i.e. to be inferior to <code>target_min</code> (if the start-up ended).
<code>ptox_targ</code>	Estimated probabilities to be in the targeted interval $[\text{target_min}, \text{target_max}]$ (if the start-up ended).
<code>ptox_sup_targ</code>	Estimated probabilities of overdosing, i.e. to be superior to <code>target_max</code> (if the start-up ended).
<code>(cdose1, cdose2)</code>	NEXT RECOMMENDED COMBINATION.
<code>inconc</code>	Boolean indicating if trial must stop for under/over dosing.
<code>early_conc</code>	Boolean indicating if trial can be stopped earlier for finding the MTD.

Author(s)

Jacques-Henri Jourdan and Marie-Karelle Riviere-Jourdan <eldamjh@gmail.com>

References

Riviere, M-K., Yuan, Y., Dubois, F., and Zohar, S. (2014). A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. *Pharmaceutical Statistics*.

See Also

[CombIncrease_sim](#).

Examples

```
prior_a1 = c(0.12, 0.2, 0.3, 0.4, 0.5)
prior_a2 = c(0.2, 0.3, 0.4)
toxicity1 = c(0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1)
dose1 = c(1,1,1,2,2,2,3,3,3,3,3,3,3,3,4,4,4)
dose2 = c(1,1,1,2,2,2,3,3,3,2,2,2,1,1,1,1,1)
t_tox = c(rep(+Inf,8),2.9,+Inf,4.6,+Inf,+Inf,+Inf,+Inf,+Inf,+Inf,5.2)
follow = c(rep(6,15), 4.9, 3.1, 1.3)

next1 = CombIncrease_next(ndose_a1=5, ndose_a2=3, target=0.3,
  target_min=0.2, target_max=0.4, prior_tox_a1=prior_a1,
  prior_tox_a2=prior_a2, cohort=3, final=FALSE, pat_incl=18,
  dose_adm1=dose1, dose_adm2=dose2, toxicity=toxicity1, c_over=1,
  cmin_overunder=3, cmin_recom=1, early_stop=1, alloc_rule=1)
next1

next2 = CombIncrease_next(ndose_a1=5, ndose_a2=3, target=0.3,
  target_min=0.2, target_max=0.4, prior_tox_a1=prior_a1, prior_tox_a2=prior_a2,
  cohort=3, final=FALSE, pat_incl=18, dose_adm1=dose1,
  dose_adm2=dose2, tite=TRUE, time_full=6, time_tox=t_tox,
  time_follow=follow, c_over=1, cmin_overunder=3, cmin_recom=1,
  early_stop=1, alloc_rule=1)
next2
```

CombIncrease_sim

Combination design Simulator using Logistic model

Description

CombIncrease_sim is used to generate simulation replicates of phase I clinical trial for combination studies where the toxicity and efficacy of both agents is assumed to increase with the dose using the design proposed by Riviere et al. entitled "A Bayesian dose-finding design for drug combination clinical trials based on the logistic model".

Usage

```
CombIncrease_sim(ndose_a1, ndose_a2, p_tox, target, target_min, target_max,
  prior_tox_a1, prior_tox_a2, n_cohort, cohort, tite=FALSE, time_full=0,
  poisson_rate=0, nsim, c_e=0.85, c_d=0.45, c_stop=0.95, c_t=0.5, c_over=0.25,
  cmin_overunder=2, cmin_mtd=3, cmin_recom=1, startup=1, alloc_rule=1,
  early_stop=1, init_dose_1=1, init_dose_2=1, nburn=2000, niter=5000, seed=14061991)
```

Arguments

ndose_a1	Number of dose levels for agent 1.
ndose_a2	Number of dose levels for agent 2.
p_tox	A matrix of the true toxicity probabilities associated with the combinations. True toxicity probabilities should be entered with agent 1 in row and agent 2 in column, with increasing toxicity probabilities with both row and column numbers (see examples).
target	Toxicity (probability) target.
target_min	Minimum of the targeted toxicity interval.
target_max	Maximum of the targeted toxicity interval.
prior_tox_a1	A vector of initial guesses of toxicity probabilities associated with the doses of agent 1. Must be of length ndose_a1.
prior_tox_a2	A vector of initial guesses of toxicity probabilities associated with the doses of agent 2. Must be of length ndose_a2.
n_cohort	Total number of cohorts to include in the trial.
cohort	Cohort size.
tite	A boolean indicating if the toxicity is considered as a time-to-event outcome (TRUE), or as a binary outcome (default value FALSE).
time_full	Full follow-up time window. This argument is used only if tite=TRUE.
poisson_rate	A value indicating the rate for the Poisson process used to simulate patient arrival, i.e. expected number of arrivals per observation window. This argument is used only if tite=TRUE.
nsim	Number of simulations.
c_e	Probability threshold for dose-escalation. The default value is set at 0.85.
c_d	Probability threshold for dose-deescalation. The default value is set at 0.45.
c_stop	Probability threshold for early trial termination due to over-toxicity or under-toxicity (see details). The default value is set at 0.95.
c_t	Probability threshold for early trial termination for finding the MTD (see details). The default value is set at 0.5.
c_over	Probability threshold to control over-dosing (see details).
cmin_overunder	Minimum number of cohorts to be included at the lowest/highest combination before possible early trial termination for over-toxicity or under-toxicity (see details). The default value is set at 2.

cmin_mtd	Minimum number of cohorts to be included at the recommended combination before possible early trial termination for finding the MTD (see details). The default value is set at 3.
cmin_recom	Minimum number of cohorts to be included at the recommended combination at the end of the trial. The default value is set at 1.
startup	Integer (0, 1, 2, or 3) indicating which start-up phase is used (see details). The default value is set at 1.
alloc_rule	Integer (1, 2, or 3) indicating which allocation rule is used (see details). The default value is set at 1.
early_stop	Integer (1, 2, or 3) indicating which early stopping rule is used (see details). The default value is set at 1.
init_dose_1	Initial dose for agent 1. The default is 1.
init_dose_2	Initial dose for agent 2. The default is 1.
nburn	Number of burn-in for HMC. The default value is set at 2000.
niter	Number of iterations for HMC. The default value is set at 5000.
seed	Seed of the random number generator. Default value is set at 14061991.

Details

Start-up phase:

- startup=0: No startup phase: the first tested combination is forced to be the initial combination. The following ones use the normal allocation rule..
- startup=1 (Riviere et al 2014): Begin at the initial combination and increase both agent (+1, +1) until the first toxicity is observed or maximum combination is reached.
- startup=2: Begin at the initial combination and increase agent 1 (+1, 0) until a toxicity is observed or maximum dose is reached. Then begin at (init_dose1,init_dose2+1) and increase agent 2 (0, +1) until a toxicity is observed or maximum dose is reached.
- startup=3: Begin at the initial combination and increase alternatively each agent (+1, 0) then (0, +1) until the first toxicity is observed or maximum combination is reached.

Allocation rule:

- alloc_rule=1 (Riviere et al 2014): If $P(\text{toxicity probability at combination } (i,j) < \text{target}) > c_e$: among combinations in the neighborhood $(-1, +1), (0, +1), (+1, 0), (+1, -1)$, choose the combination with a higher estimated toxicity probability than the current combination and with the estimated toxicity probability closest to target. If $P(\text{toxicity probability at combination } (i,j) > \text{target}) > 1 - c_d$: among neighborhood $(-1, +1), (-1, 0), (0, -1), (+1, -1)$, choose the combination with a lower estimated toxicity probability than the current combination and with the estimated toxicity probability closest to target. Otherwise, remain on the same combination.
- alloc_rule=2: Among combinations already tested and combinations in the neighborhood $(-1, 0), (-1, +1), (0, +1), (+1, 0), (+1, -1), (0, -1), (-1, -1)$ of a combination tested, choose the combination with the highest posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$ while controlling overdosing i.e. $P(\text{toxicity probability at combination } (i,j) > \text{target_max}) < c_{\text{over}}$.

- `alloc_rule=3`: Among combinations in the neighborhood $(-1, 0)$, $(-1, +1)$, $(0, +1)$, $(+1, 0)$, $(+1, -1)$, $(0, -1)$, $(-1, -1)$ of the current combination, choose the combination with the highest posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$ while controlling overdosing i.e. $P(\text{toxicity probability at combination } (i,j) > \text{target_max}) < c_over$.

Early stopping for over-dosing: If the current combination is the lowest $(1, 1)$ and at least `cmin_overunder` cohorts have been included at that combination and $P(\text{toxicity probability at combination } (i,j) > \text{target}) \geq c_stop$ then stop the trial and do not recommend any combination.

Early stopping for under-dosing: If the current combination is the highest and at least `cmin_overunder` cohorts have been included at that combination and $P(\text{toxicity probability at combination } (i,j) < \text{target}) \geq c_stop$ then stop the trial and do not recommend any combination.

Early stopping for identifying the MTD:

- `early_stop=1` (Riviere et al 2014): No stopping rule, include patients until maximum sample size is reached.
- `early_stop=2`: If the next recommended combination has been tested on at least `cmin_mtd` cohorts and has a posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$ that is $\geq c_t$ and also control overdosing i.e. $P(\text{toxicity probability at current combination} > \text{target_max}) < c_over$ then stop the trial and recommend this combination.
- `early_stop=3`: If at least `cmin_mtd` cohorts have been included at the next recommended combination then stop the trial and recommend this combination.

Stopping at the maximum sample size: If the maximum sample size is reached and no stopping rule is met, then the recommended combination is the one that was tested on at least `cmin_recom` cohorts and with the highest posterior probability to be in the targeted interval $[\text{target_min}, \text{target_max}]$.

Value

An object of class "CombIncrease_sim" is returned, consisting of the operating characteristics of the design specified. Objects generated by `CombIncrease_sim` contain at least the following components:

<code>rec_dose</code>	Percentage of combination selection.
<code>n_pat_dose</code>	Mean number of patients at each combination.
<code>n_tox_dose</code>	Mean number of toxicities at each combination.
<code>inconc</code>	Percentage of inclusive trials.
<code>early_conc</code>	Percentage of trials stopping with criterion for finding MTD.
<code>nsim</code>	Number of simulations (if function stopped while executed, return the current number of simulations performed with associated other outputs).
<code>pat_tot</code>	Total mean number of patients accrued.
<code>tab_pat</code>	Vector with the number of patients included for each simulation.

Author(s)

Jacques-Henri Jourdan and Marie-Karelle Riviere-Jourdan <eldamjh@gmail.com>

References

Riviere, M-K., Yuan, Y., Dubois, F., and Zohar, S. (2014). A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. *Pharmaceutical Statistics*.

See Also

[CombIncrease_next](#).

Examples

```
p_tox_sc1 = matrix(c(0.05,0.10,0.15,0.30,0.45,
                    0.10,0.15,0.30,0.45,0.55,
                    0.15,0.30,0.45,0.50,0.60),nrow=5,ncol=3)
prior_a1 = c(0.12, 0.2, 0.3, 0.4, 0.5)
prior_a2 = c(0.2, 0.3, 0.4)

sim1 = CombIncrease_sim(ndose_a1=5, ndose_a2=3, p_tox=p_tox_sc1, target=0.30,
                        target_min=0.20, target_max=0.40, prior_tox_a1=prior_a1,
                        prior_tox_a2=prior_a2, n_cohort=20, cohort=3, tite=FALSE, nsim=2000,
                        c_over=1, cmin_overunder=3, cmin_recom=1, startup=1, alloc_rule=1,
                        early_stop=1, seed=14061991)
sim1

# Dummy example, running quickly
useless = CombIncrease_sim(ndose_a1=3, ndose_a2=2,
                          p_tox=matrix(c(0.05,0.15,0.30,0.15,0.30,0.45),nrow=3), target=0.30,
                          target_min=0.20, target_max=0.40, prior_tox_a1=c(0.2,0.3,0.4),
                          prior_tox_a2=c(0.2,0.3), n_cohort=2, cohort=2, nsim=1)
```

Index

* **package design survival**
 dfcomb-package, [2](#)

CombIncrease_next, [3](#), [10](#)
CombIncrease_sim, [6](#), [6](#)

dfcomb(dfcomb-package), [2](#)
dfcomb-package, [2](#)

print.CombIncrease_next
 (CombIncrease_next), [3](#)
print.CombIncrease_sim
 (CombIncrease_sim), [6](#)